CORRECTION: FDA CDER Impact Story - A CDER Study of Factors that May Predict the Likelihood of Generic Drug Marketing Applications - Drug Information Update

If your email program has trouble displaying this email, view it as a web page. Correction: Incorrect headline was used. Correct headline is below. FDA CDER Impact Story: Retrospective investigation of new drug approvals and their use as reference listed drugs for generic drug applications indicates opportunities for facilitating generic drug development Increasing generic drug competition can help patients to have access to more affordable therapies, which is a critical part of the CDER mission. CDER investigations identify drug and regulatory characteristics that appear to facilitate generic drug development. Learn More This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov. Stay Connected with U.S. Food and Drug Administration:         SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA